TR 383 Mouse Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
1-AMINO-2,4-DIBROMOANTHRAQUINONE
NTP Experiment-Test: 05061-02 Report: PEIRPT05
Study Type: CHRONIC Date: 05/19/95
Route: DOSED FEED Time: 16:51:50
Facility: TSI Mason Research
Chemical CAS #: 81-49-2
Lock Date: 03/25/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05061-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-AMINO-2,4-DIBROMOANTHRAQUINONE Date: 05/19/95
Route: DOSED FEED Time: 16:51:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATE 1.0% 2.0%
D 71UF 71LF 71HF
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60
Scheduled Sacrifice 10 10 10
Early Deaths
Moribund 5 11 11
Dead 6 5 6
Survivors
Terminal Sacrifice 38 33 33
Moribund 1
Dead 1
Animals Examined Microscopically 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (60) (55) (57)
Basosquamous Tumor Malignant, Metastatic,
Uterus 1 (2%)
Gallbladder (59) (57) (54)
Basosquamous Tumor Malignant, Metastatic,
Uterus 1 (2%)
Intestine Large, Colon (60) (60) (58)
Intestine Small, Duodenum (58) (60) (56)
Intestine Small, Jejunum (57) (60) (56)
Intestine Small, Ileum (58) (60) (56)
Liver (60) (60) (60)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hemangioma 1 (2%)
Hepatoblastoma 2 (3%)
Hepatocellular Carcinoma 10 (17%) 15 (25%)
Hepatocellular Carcinoma, Multiple 13 (22%) 13 (22%)
Hepatocellular Adenoma 6 (10%) 6 (10%) 7 (12%)
Hepatocellular Adenoma, Multiple 41 (68%) 49 (82%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 3 (5%) 4 (7%)
Mesentery (6) (9) (8)
Basosquamous Tumor Malignant, Metastatic,
Uterus 1 (17%)
Fibrosarcoma, Metastatic, Skin 1 (11%)
Sarcoma, Metastatic, Stomach, Forestomach 1 (13%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 2 (22%) 3 (38%)
Pancreas (60) (60) (59)
Basosquamous Tumor Malignant, Metastatic,
Page 2
NTP Experiment-Test: 05061-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-AMINO-2,4-DIBROMOANTHRAQUINONE Date: 05/19/95
Route: DOSED FEED Time: 16:51:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATE 1.0% 2.0%
D 71UF 71LF 71HF
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Uterus 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%) 2 (3%)
Salivary Glands (59) (60) (57)
Stomach, Forestomach (58) (60) (60)
Sarcoma 1 (2%)
Squamous Cell Carcinoma 12 (20%) 11 (18%)
Squamous Cell Papilloma 2 (3%) 16 (27%) 15 (25%)
Squamous Cell Papilloma, Multiple 4 (7%) 14 (23%)
Stomach, Glandular (59) (58) (58)
Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 3 (5%) 3 (5%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (59)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (59) (58)
Carcinoma 1 (2%)
Squamous Cell Carcinoma, Metastatic 1 (2%)
Adrenal Medulla (59) (59) (58)
Islets, Pancreatic (49) (50) (48)
Adenoma 2 (4%) 1 (2%)
Pituitary Gland (51) (55) (52)
Pars Distalis, Adenoma 1 (2%) 8 (15%) 4 (8%)
Pars Distalis, Adenoma, Multiple 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Pars Nervosa, Adenoma 1 (2%)
Thyroid Gland (60) (60) (58)
Follicular Cell, Adenoma 3 (5%) 1 (2%) 2 (3%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05061-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-AMINO-2,4-DIBROMOANTHRAQUINONE Date: 05/19/95
Route: DOSED FEED Time: 16:51:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATE 1.0% 2.0%
D 71UF 71LF 71HF
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (59) (51) (57)
Basosquamous Tumor Malignant, Metastatic,
Uterus 1 (2%)
Granulosa Cell Tumor Benign 1 (2%)
Hemangioma 1 (2%)
Luteoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%) 3 (5%)
Uterus (59) (60) (59)
Leiomyoma 2 (3%)
Polyp Stromal 2 (3%)
Sarcoma Stromal 3 (5%)
Cervix, Basosquamous Tumor Malignant 1 (2%)
Vagina (1)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (59) (59)
Lymph Node (7) (12) (12)
Bronchial, Sarcoma, Metastatic, Stomach,
Forestomach 1 (8%)
Mediastinal, Squamous Cell Carcinoma,
Metastatic, Stomach, Forestomach 1 (8%) 1 (8%)
Renal, Basosquamous Tumor Malignant,
Metastatic, Uterus 1 (14%)
Lymph Node, Mandibular (38) (55) (41)
Lymph Node, Mesenteric (56) (56) (52)
Basosquamous Tumor Malignant, Metastatic,
Uterus 1 (2%)
Sarcoma, Metastatic, Stomach, Forestomach 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%) 1 (2%)
Spleen (60) (60) (59)
Hemangioma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Thymus (49) (48) (42)
Osteosarcoma, Metastatic, Bone 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05061-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-AMINO-2,4-DIBROMOANTHRAQUINONE Date: 05/19/95
Route: DOSED FEED Time: 16:51:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATE 1.0% 2.0%
D 71UF 71LF 71HF
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (35) (35) (30)
Fibroadenoma 1 (3%)
Skin (60) (60) (60)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 2 (3%) 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (48) (59)
Rib, Osteosarcoma 1 (2%)
Skeletal Muscle (4) (2) (2)
Abdominal, Fibrosarcoma, Metastatic, Skin 1 (50%)
Diaphragm, Basosquamous Tumor Malignant,
Metastatic, Uterus 1 (25%)
Diaphragm, Squamous Cell Carcinoma,
Metastatic, Stomach, Forestomach 1 (50%) 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (59) (60) (60)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (59)
Alveolar/Bronchiolar Adenoma 4 (7%) 18 (30%) 14 (24%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (3%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (3%)
Basosquamous Tumor Malignant, Metastatic,
Uterus 1 (2%)
Hemangioma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Nose (58) (55) (53)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 05061-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-AMINO-2,4-DIBROMOANTHRAQUINONE Date: 05/19/95
Route: DOSED FEED Time: 16:51:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATE 1.0% 2.0%
D 71UF 71LF 71HF
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1) (3) (2)
Adenoma 1 (100%) 2 (67%) 2 (100%)
Carcinoma 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (54) (60)
Osteosarcoma, Metastatic, Bone 1 (2%)
Urinary Bladder (59) (60) (60)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60)
Lymphoma Malignant Histiocytic 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%)
Lymphoma Malignant Mixed 9 (15%) 13 (22%) 13 (22%)
Lymphoma Malignant Undifferentiated Cell 2 (3%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05061-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-AMINO-2,4-DIBROMOANTHRAQUINONE Date: 05/19/95
Route: DOSED FEED Time: 16:51:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATE 1.0% 2.0%
D 71UF 71LF 71HF
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 32 55 59
Total Primary Neoplasms 45 158 169
Total Animals with Benign Neoplasms 24 51 58
Total Benign Neoplasms 29 103 110
Total Animals with Malignant Neoplasms 14 40 38
Total Malignant Neoplasms 16 55 59
Total Animals with Metastatic Neoplasms 2 4 6
Total Metastatic Neoplasm 12 18 24
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05061-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-AMINO-2,4-DIBROMOANTHRAQUINONE Date: 05/19/95
Route: DOSED FEED Time: 16:51:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATE 1.0% 2.0%
D 71UM 71LM 71HM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60
Scheduled Sacrifice 10 9 10
Early Deaths
Moribund 7 23 21
Dead 3 5 6
Accident 1
Survivors
Terminal Sacrifice 40 22 23
Animals Examined Microscopically 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (56) (56) (51)
Sarcoma, Metastatic, Stomach, Forestomach 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%) 1 (2%)
Intestine Large, Colon (60) (58) (60)
Mast Cell Tumor Malignant 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Intestine Large, Rectum (58) (58) (58)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Intestine Large, Cecum (59) (60) (60)
Adenocarcinoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Intestine Small, Duodenum (60) (59) (56)
Mast Cell Tumor Malignant 1 (2%)
Polyp Adenomatous 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Intestine Small, Jejunum (60) (56) (58)
Mast Cell Tumor Malignant 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Intestine Small, Ileum (60) (58) (57)
Adenocarcinoma 1 (2%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Liver (60) (60) (60)
Page 8
NTP Experiment-Test: 05061-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-AMINO-2,4-DIBROMOANTHRAQUINONE Date: 05/19/95
Route: DOSED FEED Time: 16:51:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATE 1.0% 2.0%
D 71UM 71LM 71HM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Fibrosarcoma, Metastatic, Stomach,
Forestomach 1 (2%)
Hemangiosarcoma 2 (3%) 1 (2%)
Hemangiosarcoma, Multiple 3 (5%)
Hepatoblastoma 3 (5%) 5 (8%)
Hepatocellular Carcinoma 8 (13%) 16 (27%) 12 (20%)
Hepatocellular Carcinoma, Multiple 1 (2%) 3 (5%) 9 (15%)
Hepatocellular Adenoma 4 (7%) 11 (18%) 12 (20%)
Hepatocellular Adenoma, Multiple 6 (10%) 29 (48%) 31 (52%)
Hepatocholangiocarcinoma, Multiple 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Stomach, Forestomach 1 (2%)
Squamous Cell Carcinoma, Metastatic, Tissue
NOS 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 4 (7%) 4 (7%)
Mesentery (2) (8) (9)
Sarcoma, Metastatic, Stomach, Forestomach 1 (13%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 2 (25%) 5 (56%)
Pancreas (60) (59) (58)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Stomach, Forestomach 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%) 1 (2%)
Salivary Glands (60) (59) (60)
Stomach, Forestomach (59) (59) (60)
Leiomyosarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Squamous Cell Carcinoma 12 (20%) 14 (23%)
Squamous Cell Papilloma 11 (19%) 11 (18%)
Squamous Cell Papilloma, Multiple 2 (3%) 5 (8%)
Stomach, Glandular (59) (59) (59)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 3 (5%) 4 (7%)
Tooth (4) (7)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05061-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-AMINO-2,4-DIBROMOANTHRAQUINONE Date: 05/19/95
Route: DOSED FEED Time: 16:51:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATE 1.0% 2.0%
D 71UM 71LM 71HM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (60) (60)
Adenoma 2 (3%) 1 (2%)
Sarcoma, Metastatic, Stomach, Forestomach 1 (2%)
Adrenal Medulla (60) (59) (60)
Pheochromocytoma Benign 1 (2%)
Pituitary Gland (52) (54) (56)
Pars Distalis, Adenoma 2 (4%)
Thyroid Gland (59) (59) (59)
C-Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1) (1)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Coagulating Gland (1) (1) (1)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (100%) 1 (100%)
Epididymis (59) (60) (60)
Fibrosarcoma, Metastatic, Stomach,
Forestomach 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Stomach, Forestomach 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%) 1 (2%)
Preputial Gland (21) (16) (13)
Squamous Cell Carcinoma 2 (10%)
Prostate (57) (55) (57)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic,
Preputial Gland 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Seminal Vesicle (59) (59) (55)
Fibrosarcoma, Metastatic, Stomach,
Forestomach 1 (2%)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Testes (60) (59) (60)
Sarcoma, Metastatic, Stomach, Forestomach 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Page 10
NTP Experiment-Test: 05061-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-AMINO-2,4-DIBROMOANTHRAQUINONE Date: 05/19/95
Route: DOSED FEED Time: 16:51:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATE 1.0% 2.0%
D 71UM 71LM 71HM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Forestomach 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (59) (59) (59)
Mast Cell Tumor Malignant 1 (2%)
Lymph Node (10) (8) (11)
Lumbar, Histiocytic Sarcoma 1 (13%)
Mediastinal, Histiocytic Sarcoma 1 (13%)
Mediastinal, Squamous Cell Carcinoma,
Metastatic, Stomach, Forestomach 2 (25%) 1 (9%)
Pancreatic, Histiocytic Sarcoma 1 (13%)
Pancreatic, Squamous Cell Carcinoma,
Metastatic, Stomach, Forestomach 1 (9%)
Renal, Histiocytic Sarcoma 1 (13%)
Lymph Node, Mandibular (38) (43) (36)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Lymph Node, Mesenteric (54) (56) (55)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Sarcoma, Metastatic, Stomach, Forestomach 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 2 (4%)
Spleen (60) (60) (58)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant 2 (3%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Thymus (44) (44) (41)
Mast Cell Tumor Malignant 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (57) (58)
Mast Cell Tumor Malignant 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Fibroma 2 (3%) 2 (4%) 1 (2%)
Subcutaneous Tissue, Fibroma, Multiple 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 3 (5%) 8 (14%) 2 (3%)
Subcutaneous Tissue, Sarcoma 1 (2%)
Page 11
NTP Experiment-Test: 05061-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-AMINO-2,4-DIBROMOANTHRAQUINONE Date: 05/19/95
Route: DOSED FEED Time: 16:51:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATE 1.0% 2.0%
D 71UM 71LM 71HM
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (3) (3) (3)
Abdominal, Squamous Cell Carcinoma,
Metastatic, Stomach, Forestomach 2 (67%)
Diaphragm, Sarcoma, Metastatic, Stomach,
Forestomach 1 (33%)
Diaphragm, Squamous Cell Carcinoma,
Metastatic, Stomach, Forestomach 2 (67%) 1 (33%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (60) (60)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60)
Alveolar/Bronchiolar Adenoma 7 (12%) 23 (38%) 20 (33%)
Alveolar/Bronchiolar Adenoma, Multiple 6 (10%) 9 (15%)
Alveolar/Bronchiolar Carcinoma 3 (5%) 3 (5%) 1 (2%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Hepatocellular Carcinoma, Metastatic 1 (2%) 2 (3%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (3%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic, Stomach, Forestomach 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 3 (5%)
Mediastinum, Hemangiosarcoma, Metastatic,
Spleen 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1) (1) (1)
Fibrosarcoma 1 (100%)
Harderian Gland (2) (2) (1)
Adenoma 2 (100%) 2 (100%) 1 (100%)
Lacrimal Gland (1)
Adenoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 12
NTP Experiment-Test: 05061-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-AMINO-2,4-DIBROMOANTHRAQUINONE Date: 05/19/95
Route: DOSED FEED Time: 16:51:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATE 1.0% 2.0%
D 71UM 71LM 71HM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (52) (60)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 2 (4%)
Urinary Bladder (59) (59) (59)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymphoma Malignant Histiocytic 1 (2%) 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%) 1 (2%)
Lymphoma Malignant Mixed 7 (12%) 3 (5%) 5 (8%)
Lymphoma Malignant Undifferentiated Cell 2 (3%) 2 (3%) 1 (2%)
Mesothelioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 13
NTP Experiment-Test: 05061-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 1-AMINO-2,4-DIBROMOANTHRAQUINONE Date: 05/19/95
Route: DOSED FEED Time: 16:51:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATE 1.0% 2.0%
D 71UM 71LM 71HM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 38 53 55
Total Primary Neoplasms 58 168 151
Total Animals with Benign Neoplasms 20 47 50
Total Benign Neoplasms 25 90 94
Total Animals with Malignant Neoplasms 26 40 40
Total Malignant Neoplasms 33 78 57
Total Animals with Metastatic Neoplasms 4 7 9
Total Metastatic Neoplasm 4 37 36
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 14
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 85877-85877/85877
--multipart-boundary--